肤痒舒洗剂熏洗治疗肛门瘙痒症46例

目的 探讨肤痒舒洗剂治疗肛门瘙痒症的疗效.方法 将91例肛门瘙痒症患者分为两组,治疗组46例采用肤痒舒洗剂熏洗,对照组45例采用氢化可的松软膏外涂.结果 治疗组总有效率明显优于对照组(P＜0.05).结论 肤痒舒洗剂是较为简单而有效的治疗肛门瘙痒症的方法.     

局部注射亚甲蓝配合苦参汤坐浴治疗肛门瘙痒症40例

目的：观察局部注射亚甲蓝配合苦参汤坐浴治疗肛门瘙痒症的疗效。方法对原发性肛门瘙痒症的40例患者,采用亚甲蓝在肛周皮损处点状注射,术后配合苦参汤坐浴,观察自觉瘙痒症状和皮损恢复情况。结果随访1年后59例患者的皮损恢复正常,瘙痒消失;1例患者复发。结论局部注射亚甲蓝配合苦参汤坐浴治疗肛门瘙痒症的疗效可靠。     

地榆槐角丸加减方配合外用肤痔清软膏治疗混合痔的疗效观察

目的探讨地榆槐角丸加减方配合外用肤痔清软膏治疗混合痔的临床疗效。方法选取2015年6月至2016年6月在我院就诊的80例混合痔患者,随机分为观察组(地榆槐角丸加减方配合外用肤痔清软膏)和对照组(常规治疗)各40例。对比两组临床疗效。结果观察组总有效率92.50%,与对照组总有效率70.00%比较,显著升高(P<0.05)。治疗前两组便血、脱出、痔黏膜、痔核大小和肛门坠胀疼痛评分比较,差异无统计学意义(P>0.05)。治疗后两组便血、脱出、痔黏膜、痔核大小和肛门坠胀疼痛评分均显著低于治疗前(P<0.05),且观察组便血、脱出、痔黏膜、痔核大小和肛门坠胀疼痛评分显著低于对照组(P<0.05)。结论地榆槐角丸加减方配合外用肤痔清软膏治疗混合痔的疗效显著,值得临床推广。     

自拟活血苦参汤坐浴治疗血栓外痔的临床研究

目的观察活血苦参汤坐浴治疗血栓外痔的临床疗效。方法将120例血栓外痔患者随机分为两组,治疗组60例,对照组60例,治疗组采用中药活血苦参汤坐浴治疗,对照组采用高锰酸钾溶液坐浴治疗,对比观察两组患者疗效,治疗后疼痛评分、疼痛完全缓解时间及血栓痔核完全消失时间。结果治疗组治愈有效率、坐浴后肛周疼痛评分、坐浴后肛周疼痛完全缓解及肛门部血栓痔核完全消失时间,与对照组相比具有统计学差异(P0.05)。结论活血苦参汤坐浴治疗血栓外痔优于传统的高锰酸钾溶液坐浴。     

胎盘注射液、肤痔清软膏局部封闭治疗外阴上皮内非瘤样病变的临床效果观察

目的：观察胎盘注射液、肤痔清软膏局部封闭治疗外阴上皮内非瘤样病变的临床效果。方法对我院250例外阴上皮内非瘤样病变患者的临床资料,根据不同治疗方法将患者分为观察组和对照组,对照组采用肤痔清软膏联合超声聚焦治疗,观察组在对照组治疗基础上采用胎盘注射液穴位、局部封闭治疗。对比观察两组患者的治疗效果。结果观察组临床治疗中有效率明显高于对照组,两组数据对比差异有统计学意义（ P＜0．05）。结论对外阴上皮内非瘤样病变患者在对症治疗基础上采用胎盘注射液、肤痔清软膏局部封闭治疗的疗效明显,可以提高外阴的局部营养,疗效安全可靠。     

肤痔清软膏辅助治疗流行性腮腺炎合并睾丸炎临床观察

目的观察肤痔清软膏辅助治疗流行性腮腺炎合并睾丸炎的临床疗效。方法将80例流行性腮腺炎合并睾丸炎患者随机分为治疗组和对照组各40例,2组均给予常规治疗,治疗组在次基础上采用肤痔清软膏清洗患处,观察2组临床疗效、体温消退时间、睾丸肿痛消退时间。结果治疗组总有效率高于对照组、退热时间和睾丸肿痛消退时间均短于对照组,差异均有统计学意义（P〈0．05）。结论肤痔清软膏辅助治疗流行性腮腺炎合并睾丸炎起效快,疗效确切,安全可靠。     

肛门手术愈合后肛周潮湿52例临床观察

为观察肛门术后伤口愈合1～2个月后肛周潮湿临床病例治疗情况,将52例符合观察条件的患者随机分为治疗组和对照组,治疗组便后使用坐浴II号坐浴并使用牛黄痔清栓及甲硝唑栓塞肛治疗,对照组使用口服抗组胺药物加外用派瑞松软膏治疗,10天为一个疗程,两个疗程后对肛周潮湿、瘙痒症状根据疗效标准进行评价。结果显示,治疗组总有效率89.7%,对照组总有效率73.9%(P<0.05)。提示我科坐浴II号配合牛黄痔清栓及甲硝唑栓对于肛门手术愈合后1～2个月肛周潮湿及瘙痒情况有较好疗效。     

黄苦痔消肿洗剂与高锰酸钾对痔术后肛门疼痛、水肿疗效的对比观察

目的观察黄苦痔消肿洗剂治疗痔后肛门疼痛、水肿等并发症的临床效果。方法选取我院近期内收治的287例混合痔患者,均给与内扎外剥术进行治疗。手术治疗后将287例患者随机分为A、B两组,A组143例给予高锰酸钾便后坐浴治疗,B组144例患者给予黄苦痔消肿洗剂熏后坐浴治疗,比较两组患者治疗后的临床效果。结果经黄苦痔消肿洗剂坐浴治疗的B组患者与应用高锰酸钾坐浴治疗的A组患者在治疗术后肛门水肿、便后肛门疼痛方面比较具有明显优势。结论临床应用黄苦痔消肿洗剂治疗痔手术后并发症时疗效显著且安全性高,值得临床广泛推广应用。     

妇洁康洗剂治疗肛门瘙痒症的疗效观察

目的:分析妇洁康洗剂治疗肛门瘙痒症的疗效.方法:纳入2019年4月—2020年7月我院收治的86例肛门瘙痒症患者,按抛硬币随机法分组,各43例.对照组以常规温水坐浴治疗,治疗组联合妇洁康洗剂治疗,对比两组疗效及瘙痒症状评分变化.结果:治疗组瘙痒消失时间、皮损恢复正常时间均短于对照组(P<0.05);治疗前两组瘙痒症状评分比较差异无统计学意义(P>0.05),治疗后两组瘙痒症状评分较治疗前显著降低且治疗组治疗后瘙痒症状评分低于对照组(P<0.05);治疗组治疗有效率高于对照组(P<0.05);治疗组DLQI评分高于对照组而复发率低于对照组(P<0.05).结论:在肛门瘙痒症中以妇洁康洗剂治疗可以缩短患者症状恢复时间和住院时间,改善瘙痒症状,提高疗效、生活质量,并降低复发率,值得应用.     

盐酸多西环素肠溶胶囊联合肤痔清软膏治疗中重度寻常痤疮的疗效观察

目的：观察盐酸多西环素肠溶胶囊联合肤痔清软膏治疗中重度痤疮的疗效。方法70例中重度痤疮男性患者随机分为用盐酸多西环素肠溶胶囊联合肤痔清软膏为治疗组及单用盐酸多西环素肠溶胶囊为对照组,各35例,治疗3周及6周后统计疗效。结果治疗组及对照组总有效率于3周及6周分别为73.53%和40.00%;82.35%和77.14%,前者两组比较差异有统计学意义（P〈0.05）,后者两组比较差异无统计学意义（P〉0.05）。结论盐酸多西环素肠溶胶囊联合肤痔清软膏治疗中重度痤疮效果显著,联合应用明显缩短疗程,减少盐酸多西环素肠溶胶囊用量,减少不良反应,值得临床推广。     

Synthesis,Cytotoxicity and Antileishmanial Activity of Some N-(2-(indol-3-yl)ethyl)-7-chloroquinolin-4-amines

We report herein the condensation of 4,7-dichloroquinoline (1) with tryptamine (2) and D-tryptophan methyl ester (3) . Hydrolysis of the methyl ester adduct (5) yielded the free acid (6) . The compounds were evaluated in vitro for activity against four different species of Leishmania promastigote forms and for cytotoxic activity against Kb and Vero cells. Compound (5) showed good activity against the Leishmania species tested, while all three compounds displayed moderate activity in both Kb and Vero cells.     

Efficacy of gut lavage,hemodialysis, and hemoperfusion in the therapy of paraquat or diquat intoxication

Clinical and in vitro investigations were carried out to test the efficacy of gut lavage, hemodialysis, and hemoperfusion in the treatment of poisoning with paraquat or diquat. In a patient suffering from diquat intoxication 130 times more diquat was removed by gut lavage 30 h after ingestion than was removed by complete aspiration of the gastric contents.Determination of in vitro clearances for paraquat and diquat by hemodialysis showed that, at serum concentrations of 1–2 ppm, such as are frequently encountered in poisoning in man, toxicologically relevant quantities of herbicide cannot be removed from the body. At a concentration of 20 ppm, on the other hand, hemodialysis proved to be effective, the clearance being 70 ml/min at a blood flow rate of 100 ml/min. The efficacy of hemoperfusion with coated activated charcoal was on the whole better. Especially at concentrations around 1–2 ppm, the clearance values for hemoperfusion were some 5–7 times higher than those for hemodialysis.In a patient suffering from paraquat poisoning, both hemodialysis as well as hemoperfusion were carried out. The in vitro results could be confirmed: At serum concentrations of paraquat less than 1 ppm no clearance could be obtained by hemodialysis while by hemoperfusion with activated charcoal quite high clearance values were measured and the serum level dropped down to zero.

---

Zusammenfassung Klinische Untersuchungen und Laboratoriumsversuche wurden durchgeführt, um die Wirksamkeit von Darmspülung, Hämodialyse und Hämoperfusion bei Paraquat- und Deiquat-Vergiftungen zu prüfen.Bei einem Patienten wurde 30 Std nach Deiquat-Aufnahme durch Darmspülung 130mal mehr Deiquat entfernt als durch vollständige Aspiration des Mageninhaltes. In vitro-Versuche ergaben, daß bei Blutserumkonzentrationen von 1–2 ppm, die bei Vergiftungen oft gemessen werden, durch Hämodialyse keine toxikologisch relevanten Paraquat- oder Deiquat-Mengen entfernt werden können. Dagegen erwies sich die Hämodialyse bei 20 ppm und einer Blutumlaufgeschwindigkeit von 100 ml/min mit einer Clearance von 70 ml/min als wirksam. Die Hämoperfusion mit beschicheter Aktivkohle war in diesen Versuchen aber eindeutig überlegen, denn insbesondere bei Konzentrationen um 1–2 ppm waren die Clearance-Werte 5–7mal höher als bei der Hämodialyse.Die in vitro-Ergebnisse wurden bei einem Patienten mit einer Paraquat-Vergiftung bestätigt: Bei Konzentrationen unter 1 ppm war die Hämodialyse wirkungslos, während durch Hämoperfusion relativ hohe Clearance-Werte erreicht wurden, so daß der Serumspiegel rasch unter die Nachweisgrenze abfiel.

     

In vitro studies on sterically stabilized liposomes (SL) as enzyme carriers in organophosphorus (OP) antagonism

This study describes a new approach for organophosphorous (OP) antidotal treatment by encapsulating an OP hydrolyzing enzyme, OPA anhydrolase (OPAA), within sterically stabilized liposomes. The recombinant OPAA enzyme was derived from Alteromonas strain JD6. It has broad substrate specificity to a wide range of OP compounds: DFP and the nerve agents, soman and sarin. Liposomes encapsulating OPAA (SL)* were made by mechanical dispersion method. Hydrolysis of DFP by (SL)* was measured by following an increase of fluoride ion concentration using a fluoride ion selective electrode. OPAA entrapped in the carrier liposomes rapidly hydrolyze DFP, with the rate of DFP hydrolysis directly proportional to the amount of (SL)* added to the solution. Liposomal carriers containing no enzyme did not hydrolyze DFP. The reaction was linear and the rate of hydrolysis was first order in the substrate. This enzyme carrier system serves as a biodegradable protective environment for the recombinant OP-metabolizing enzyme, OPAA, resulting in prolongation of enzymatic concentration in the body. These studies suggest that the protection of OP intoxication can be strikingly enhanced by adding OPAA encapsulated within (SL)* to pralidoxime and atropine.     

Lung disease and PKCs

The lung offers a rich opportunity for development of therapeutic strategies focused on isozymes of protein kinase C (PKCs). PKCs are important in many cellular responses in the lung, and existing therapies for pulmonary disorders are inadequate. The lung poses unique challenges as it interfaces with air and blood, contains a pulmonary and systemic circulation, and consists of many cell types. Key structures are bronchial and pulmonary vessels, branching airways, and distal air sacs defined by alveolar walls containing capillaries and interstitial space. The cellular composition of each vessel, airway, and alveolar wall is heterogeneous. Injurious environmental stimuli signal through PKCs and cause a variety of disorders. Edema formation and pulmonary hypertension (PHTN) result from derangements in endothelial, smooth muscle (SM), and/or adventitial fibroblast cell phenotype. Asthma, chronic obstructive pulmonary disease (COPD), and lung cancer are characterized by distinctive pathological changes in airway epithelial, SM, and mucous-generating cells. Acute and chronic pneumonitis and fibrosis occur in the alveolar space and interstitium with type 2 pneumocytes and interstitial fibroblasts/myofibroblasts playing a prominent role. At each site, inflammatory, immune, and vascular progenitor cells contribute to the injury and repair process. Many strategies have been used to investigate PKCs in lung injury. Isolated organ preparations and whole animal studies are powerful approaches especially when genetically engineered mice are used. More analysis of PKC isozymes in normal and diseased human lung tissue and cells is needed to complement this work. Since opposing or counter-regulatory effects of selected PKCs in the same cell or tissue have been found, it may be desirable to target more than one PKC isozyme and potentially in different directions. Because multiple signaling pathways contribute to the key cellular responses important in lung biology, therapeutic strategies targeting PKCs may be more effective if combined with inhibitors of other pathways for additive or synergistic effect. Mechanisms that regulate PKC activity, including phosphorylation and interaction with isozyme-specific binding proteins, are also potential therapeutic targets. Key isotypes of PKC involved in lung pathophysiology are summarized and current and evolving therapeutic approaches to target them are identified.     

Steroidal sapogenin contents in some domestic plants

In order to find out the values of the steroid resources for the future use. the compositions and contents of steroidal sapogenins from 13 domestic plants have been investigated. As a result,Dioscorea nipponica, D. quinqueloba andSmilax china were found to have large amount of diosgenin. And pennogenin inTrillium kamtschaticum andParis verticillata, yuccagenin inAllium fistulosum, hecogenin inAgave americana and neochlorogenin inSolanum nigum were appeared to be major steroidal sapogenins.